SHOWNOTES
This week on Telltales, the team moves from energy geopolitics to mega-cap tech cash flows and healthcare catalysts—through the lens of what actually endures: free cash flow, incentives, and execution.
[00:00] Welcome to Telltales + Cash Flow Memo setup
Mike frames the episode’s focus across energy, technology, and healthcare—and points listeners to the memo and exhibits.
[00:29] Exhibit C: Oil supply, Iran risk, and what changes (or doesn’t)
Hunt walks through how recent Middle East tensions can shift the crude supply outlook, while noting limited physical damage so far.
[02:49] Exhibit B: Natural gas, LNG dynamics, and the forward curve
The conversation pivots to natural gas fundamentals and how supply/demand expectations translate into pricing and planning.
[05:33] US fiscal picture: deficits, the dollar, and gold signals
The group discusses US Treasury math, what’s improving (and what isn’t), and how markets interpret the trajectory via gold and rates.
[09:27] Index concentration and the “Magnificent Seven” stability debate
Hunt challenges the idea that concentration equals fragility, arguing the biggest names are proving steadier than expected.
[11:49] Tesla: robotaxis, humanoid robots, and valuation as a long-dated option
They debate whether autonomy and robotics justify Tesla’s premium—and how production choices signal a strategic pivot.
[14:28] Enterprise software in an AI world: why Snowflake still matters
Snowflake’s role is framed as “memory” and infrastructure for AI systems, not just another software line item competing with new tools.
[18:30] Nvidia vs the field: scale, cash flow, and the next bottleneck
The team breaks down Nvidia’s dominance versus challengers and explores where constraints may emerge—especially around data center buildout and permitting.
[22:25] Harrow: guidance optics, management credibility, and Vivi/Vevye tailwinds
A sharp selloff meets a fundamentals discussion: conservative guidance, product momentum, and a meaningful catalyst through CVS’s PBM channel.
[25:18] FDA acceleration: priority review vouchers and faster approvals
Jason covers a rapid approval example and what it implies about timelines, costs, and the evolving regulatory playbook.
[26:16] Clinical trials shift: fewer Phase 3 requirements and higher ROI on R&D
They discuss how moving from “two Phase 3 trials” toward “one + longer follow-up” can change economics for smaller biotechs and drug development broadly.
[28:16] Vertex as a healthcare execution benchmark
In a “Nvidia of healthcare” style prompt, the group highlights Vertex as best-in-class at in-house R&D returns and sustained pipeline strength.
[29:38] Closing thoughts
A wrap on how US capital markets absorb macro shocks—and why business quality ultimately anchors long-term outcomes.
If you found this helpful, grab the Cash Flow Memo, drop a comment with the company you want covered next, and subscribe for weekly episodes on cash flow-first investing.
This podcast and the information herein are intended for informational purposes only. The views expressed herein are the author’s alone and do not constitute an offer to sell, or a recommendation to purchase, or a solicitation of an offer to buy, any security, nor a recommendation for any investment product or service. While certain information contained herein has been obtained from sources believed to be reliable, neither the author nor any of his employers or their affiliates have independently verified this information, and its accuracy and completeness cannot be guaranteed. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, timeliness or completeness of this information. The author and all employers and their affiliated persons assume no liability for this information and no obligation to update the information or analysis contained herein in the future.
